The role of antihistamines in the treatment of vasomotor rhinitis.

Abstract

BACKGROUND:

The pathogenesis of vasomotor rhinitis is not understood. It is unlikely that antihistamines, based on their H1 antagonist activity alone, would be effective in this disorder.

METHODS:

Nonetheless, at least one double-blind, placebo-controlled multicenter trial has found that intranasal azelastine relieves symptoms of this disorder better than placebo. The mechanism responsible for its beneficial effect in nonallergic rhinitis is unclear but probably relates to "anti-inflammatory/antiallergic" activities.

RESULTS:

Such mechanisms have been demonstrated for a number of different oral antihistamines, but often the concentrations required in vitro are higher than those that are normally achieved in vivo using recommended dosing. It has been postulated that intranasal administration, which can achieve high local levels, might be a factor responsible for enhancing the "anti-inflammatory/antiallergic" properties.

CONCLUSIONS:

Interpreting this information allows one to conclude that antihistamines may be potentially effective agents in vasomotor rhinitis, and are more likely to be so when administered intranasally, despite the fact that data documenting this beneficial effect are sparse.

• Authors: Phil Lieberman
• Journal: The World Allergy Organization journal (World Allergy Organ J) Vol. 2 Issue 8 Pg. 156-61 (Aug 15 2009) ISSN: 1939-4551 [Print] United States
• PMID: 24228781 (Publication Type: Journal Article)